Targeting mitochondrial bioenergetics by combination treatment with imatinib and dichloroacetate in human erythroleukemic K ‑562 and colorectal HCT‑116 cancer cells
Int J Oncol. 2024 Apr;64(4):42. doi: 10.3892/ijo.2024.5630. Epub 2024 Mar 1.ABSTRACTTumor malignant cells are characterized by dysregulation of mitochondrial bioenergetics due to the 'Warburg effect'. In the present study, this metabolic imbalance was explored as a potential target for novel cancer chemotherapy. Imatinib (IM) downregulates the expression levels of SCΟ2 and FRATAXIN (FXN) genes involved in the heme‑dependent cytochrome c oxidase biosynthesis and assembly pathway in human erythroleukemic IM‑sensitive K‑562 chronic myeloid leukemia cells (K‑562). In the present study, it was investigated whether the ...
Source: International Journal of Oncology - March 1, 2024 Category: Cancer & Oncology Authors: Maria G Kakafika Areti A Lyta George I Gavriilidis Stefanos A Tsiftsoglou Androulla N Miliotou Ioannis S Pappas Ioannis S Vizirianakis Lefkothea C Papadopoulou Asterios S Tsiftsoglou Source Type: research
